← All trials
NCT06254495
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2024
- Primary completion
- Feb 28, 2028
- Completion date
- Aug 31, 2028
- First posted
- Feb 12, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 170
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seattle GeneticsLead sponsor
- Seattle GeneticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.